| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England journal of medicine 364 (19), 1817-1825, 2011 | 8560 | 2011 |
| FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... New England Journal of Medicine 379 (25), 2395-2406, 2018 | 2668 | 2018 |
| Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo … AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ... The lancet oncology 20 (2), 282-296, 2019 | 1692 | 2019 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... The lancet oncology 23 (1), 77-90, 2022 | 894 | 2022 |
| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma … V Vilgrain, H Pereira, E Assenat, B Guiu, AD Ilonca, GP Pageaux, A Sibert, ... The Lancet Oncology 18 (12), 1624-1636, 2017 | 860 | 2017 |
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial AX Zhu, M Kudo, E Assenat, S Cattan, YK Kang, HY Lim, RTP Poon, ... Jama 312 (1), 57-67, 2014 | 686 | 2014 |
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study JM Llovet, T Decaens, JL Raoul, E Boucher, M Kudo, C Chang, YK Kang, ... Journal of Clinical Oncology 31 (28), 3509-3516, 2013 | 684 | 2013 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 535 | 2023 |
| Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study J Edeline, M Benabdelghani, A Bertaut, J Watelet, P Hammel, JP Joly, ... Journal of Clinical Oncology 37 (8), 658-667, 2019 | 511 | 2019 |
| 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer D Farge, C Frere, JM Connors, C Ay, AA Khorana, A Munoz, B Brenner, ... The Lancet Oncology 20 (10), e566-e581, 2019 | 490 | 2019 |
| Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised … E Garin, L Tselikas, B Guiu, J Chalaye, J Edeline, T de Baere, E Assenat, ... The lancet Gastroenterology & hepatology 6 (1), 17-29, 2021 | 482 | 2021 |
| Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial D Malka, P Cervera, S Foulon, T Trarbach, C de la Fouchardière, ... The lancet oncology 15 (8), 819-828, 2014 | 438 | 2014 |
| Establishment and characterization of a cell line from human circulating colon cancer cells L Cayrefourcq, T Mazard, S Joosse, J Solassol, J Ramos, E Assenat, ... Cancer research 75 (5), 892-901, 2015 | 419 | 2015 |
| Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study L Rimassa, E Assenat, M Peck-Radosavljevic, M Pracht, V Zagonel, ... The Lancet Oncology 19 (5), 682-693, 2018 | 374 | 2018 |
| Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... N Engl J Med 379 (25), 2395-2406, 2018 | 304 | 2018 |
| Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC R Lencioni, R Montal, F Torres, JW Park, T Decaens, JL Raoul, M Kudo, ... Journal of hepatology 66 (6), 1166-1172, 2017 | 221 | 2017 |
| KRASG12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma B Bournet, F Muscari, C Buscail, E Assenat, M Barthet, P Hammel, ... Clinical and translational gastroenterology 7 (3), e157, 2016 | 212 | 2016 |
| Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ... JAMA oncology 8 (11), 1571-1578, 2022 | 210 | 2022 |
| A phase 2 study of galunisertib (TGF-β1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma RK Kelley, E Gane, E Assenat, J Siebler, PR Galle, P Merle, IO Hourmand, ... Clinical and translational gastroenterology 10 (7), e00056, 2019 | 202 | 2019 |
| Interleukin 1β inhibits CAR‐induced expression of hepatic genes involved in drug and bilirubin clearance E Assenat, S Gerbal‐Chaloin, D Larrey, J Saric, JM Fabre, P Maurel, ... Hepatology 40 (4), 951-960, 2004 | 196 | 2004 |